Favipiravir, also known as T-705, is an antiviral drug that has been approved in 2014 in
Japan to treat pandemic influenza virus infections. The drug is converted intracellularly into …

Influenza virus polymerase inhibitors in clinical developmen... : Current Opinion in Infectious
Diseases Influenza virus polymerase inhibitors in clinical development : Current Opinion in …

Favipiravir is a broad-spectrum antiviral that has shown promise in treatment of influenza
virus infections. While emergence of resistance has been observed for many antiinfluenza …

Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent
RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved …

Influenza virus is a highly contagious zoonotic respiratory disease that causes seasonal
outbreaks each year and unpredictable pandemics occasionally with high morbidity and …

Over the past 3 years, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
has spread through human populations in several waves, resulting in a global health crisis …

Background The pharmacokinetics of oral favipiravir and the relationships of plasma
concentrations to antiviral effects are incompletely studied in influenza. Methods Serial …

Influenza A virus (IAV), a major cause of human morbidity and mortality, continuously
evolves in response to selective pressures. Stem-directed, broadly neutralizing antibodies …

With the rapid global spread of SARS-CoV-2, tremendous efforts have been focused upon
potential treatment strategies (Li and De Clercq 2020). Evolutionary theory has an important …

Human cytomegalovirus (HCMV) represents a major threat to human health, contributing to
both birth defects in neonates as well as organ transplant failure and opportunistic infections …